Functionalized polymeric nanoparticles loaded with indocyanine green as theranostic materials for targeted molecular near infrared fluorescence imaging and photothermal destruction of ovarian cancer cells

Lasers in Surgery and Medicine

Volumn 46, Issue 7, 2014, Pages 582-592

  Bahmani, Baharak ^a   Guerrero, Yadir ^a   Bacon, Danielle ^a   Kundra, Vikas ^b   Vullev, Valentine I ^a   Anvari, Bahman ^a  

^a University of California Riverside   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

cytoreduction; her2; laser therapy; nanomedicine; optical imaging; tumor

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INDOCYANINE GREEN; MONOCLONAL ANTIBODY; NANOPARTICLE; POLYMER;

ARTICLE; CANCER CELL; CANCER CELL DESTRUCTION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; IRRADIATION; LASER; LOW LEVEL LASER THERAPY; MATERIALS; MOLECULARLY TARGETED THERAPY; NANOMEDICINE; OVARY CANCER; PRIORITY JOURNAL; DIAGNOSTIC IMAGING; MOLECULAR IMAGING; OVARIAN NEOPLASMS; PATHOLOGY; PHOTOTHERAPY; PROCEDURES; TUMOR CELL CULTURE;

DIAGNOSTIC IMAGING; FEMALE; HUMANS; INDOCYANINE GREEN; MOLECULAR IMAGING; NANOPARTICLES; OPTICAL IMAGING; OVARIAN NEOPLASMS; PHOTOTHERAPY; POLYMERS; TUMOR CELLS, CULTURED;

EID: 84906318212     PISSN: 01968092     EISSN: 10969101     Source Type: Journal    
DOI: 10.1002/lsm.22269     Document Type: Article

References (59)

1. Holschneider CH, Berek JS,. Ovarian cancer: Epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000; 19: 3-10.
2. Bast RC Jr, Hennessy B, Mills GB,. The biology of ovarian cancer: New opportunities for translation. Nat Rev Cancer 2009; 9: 415-428.
3. Prat J,. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 2014; 124: 1-5.
4. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S, Beller U,. Carcinoma of the ovary. FIGO 26th Annual Report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006; 96 (Suppl 1): S161-S192.
5. Williams TI, Toups KL, Saggese DA, Kalli KR, Cilby WA, Muddiman DC,. Epithelial ovarian cancer: Disease etiology, treatment, detection, and investigational gene, metabolite, and protein biomarkers. J Proteome Res 2007; 6: 2936-2962.
6. Metzger-Filho O, Moulin C, D'Hondt V,. First-line systemic treatment of ovarian cancer: A critical review of available evidence and expectations for future directions. Curr Opin Oncol 2010; 22: 513-520.
7. Liu J, Matulonis UA,. New advances in ovarian cancer. Oncology 2010; 24: 721-728.
8. Zivanovic O, Aldini A, Carlson JW, Chi DS,. Advanced cytoreductive surger: American perspective. Gynecol Oncol 2009; 114 (2 Suppl): S3-S9.
9. Vergote I, van Gorp T, Amant F, Leunen K, Neven P, Berteloot P,. Timing of debulking surgery in advanced ovarian cancer. Int J Gynecol Cancer 2008; 18 (Suppl 1): 11-19.
10. Zhong W, Celli JP, Mai Z, Spring BQ, Yun SH, Hasan T,. In vivo high-resolution fluorescence microendoscopy for ovarian cancer detection and treatment monitoring. Br J Cancer 2009; 101: 2015-2022.
11. Troyan SL, Kianzad V, Gibbs-Strauss SL, Gioux S, Matsui A, Oketokoun R, Ngo L, Khamene A, Azar F, Frangioni JV,. The FLARE intraoperative near-infrared fluorescence imaging system: A first-in-human clinical trial in breast cancer sentinel lymph node mapping. Ann Surg Oncol 2009; 16: 2943-2952.
12. Vahrmeijer AL, Hutteman M, van der Vorst JR, van de Velde CJH, Frangioni JV,. Image-guided cancer surgery using near-infrared fluorescence. Nat Rev Clin Oncol 2013; 10: 507-518.
13. Kitai T, Inomoto T, Miwi M, Shikayama T,. Fluorescence navigation with indocyanine green for detecting sentinel lymph nodes in breast cancer. Breast Cancer 2005; 12: 211-215.
14. Sevick-Muraca EM, Sharma R, Rasmussen JC, Marshall MV, Wendt JA, Pham HQ, Bonefas E, Houston JP, Sampath L, Adams KE, Blanchard DK, Fisher RE, Chiang SB, Elledge R, Mawad ME,. Imaging of lymph flow in breast cancer patients after microdose administration of a near-infrared fluorophore: Feasibility study. Radiology 2008; 246: 731-741.
15. Hirche C, Murawa D, Mohr Z, Kneif S, Hunerbein M,. ICG fluorescence-guided sentinel lymph node biopsy for axillary nodal staging in breast cancer. Breast Cancer Res Treat 2010; 121: 373-378.
16. van der Vorst JR, Schaafsma BE, Verbeek FP, Swijnenburg RJ, Hutteman M, Liefers GJ, van de Velde CJ, Frangioni JV, Vahrmeijer AL,. Dose optimization for near-infrared fluorescence sentinel lymph node mapping in patients with melanoma. Br J Dermatol 2013; 168: 93-98.
17. Costa RA, Scapucin L, Moracs NS, Calucci D, Melo LA, Cardillo JA, Farah ME,. Indocyanine green-mediated photothrombosis as a new technique of treatment for persistent central serous chorioretinopathy. Curr Eye Res 2002; 25: 287-297.
18. Klein A, Szeimies RM, Baumler W, Zeman F, Schreml S, Hohenleutner U, Landthaler M, Koller M, Babilas P,. Indocyanine green-augmented diode laser treatment of port-wine stains: Clinical and histological evidence for a new treatment option from a randomized controlled trial. Br J Dermatol 2012; 167: 333-342.
19. Klein A, Baumler H, Buschmann M, Landthaler M, Babilas P,. A randomized controlled trial to optimize indocyanine green-augmented diode laser therapy of capillary malformations. Lasers Surg Med 2013; 45: 216-224.
20. Wu L, Fang S, Shi S, Deng J, Liu B, Cai L,. Hybrid polypeptide micelles loading indocyanine green for tumor imaging and photothermal effect study. Biomacromolecules 2013; 14: 3027-3033.
21. Yoon HK, Ray A, Lee YE, Kim G, Wang X, Kopelman R,. Polymer-protein hydrogel nanomatrix for stabilization of indocyanine green towards targeted fluorescence and photoacoustic bio-imaging. J Mater Chem B Mater Biol Med 2013; 1: 5611-5619.
22. Bahmani B, Lytle CY, Walker AM, Gupta S, Vullev V, Anvari B,. Effects of nano-encapsulation and PEGylation on biodistribution of indocyanine green in healthy mice: Quantitative fluorescence imaging and analysis of organs. Int J Nanomed 2013; 8: 1609-1620.
23. Steffensen KD, Waldstrom M, Andersen RF, Olsen DA, Jeppesen U, Knudsen HJ, Brandslund I, Jackobsen A,. Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors. Int J Oncol 2008; 33: 195-204.
24. Barthelemy J, Leblanc J, Goldbarg V, Wendling F, Kurtz J-E,. Pertuzumab: Development beyond breast cancer. Anticancer Res 2014; 34: 1483-1492.
25. English DP, Roque DM, Santin AD,. HER2 expression beyond breast cancer: Therapeutic implications for gynecologic malignancies. Mol Diagn Ther 2013; 17: 85-99.
26. Yan M, Parker BA, Schwab R, Kurzrock R,. HER2 aberrations in cancer: Implicatinos for therapy. Cancer Treat Rev 2014; S0305-7372 (14)00043-7: doi: 10.1016/j.ctrv.2014.1002.1008
27. Lee CH, Huntsman DG, Cheang MC, Parker RL, Brown L, Hoskins P, Miller D, Gilks CB,. Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma. Int J Gynaecol Pathol 2005; 24: 147-152.
28. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR,. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003; 21: 283-290.
29. Verri E, Guglielimini P, Puntoni M, Predelli L, Papadia A, Lorenz P, Rubagotti A, Ragni N, Boccardo F,. HER2/neu oncoprotein overexpression in epithelial ovarian cancer: Evaluation of its prevalence and prognostic significance. Clinical study. Oncology 2005; 68: 154-161.
30. Nielsen JS, Jakobsen E, Hølund B, Bertelsen K, Jacobsen A,. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer 2004; 14: 1088-1096.
31. Høgdall EVS, Christensen L, Kjaer SK, Blaakaer J, Bock JE, Glud E, Nørgaard-Pedersen B, Høgdall CK,. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma. Cancer 2003; 98: 66-73.
32. Lanitis E, Dangaj D, Hagemann IS, Song D-G, Best A, Sandaltzopoulos R, Coukos G, Powell DJ Jr., Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels. PLoS ONE 2012; 7: e49829.
33. Aina OH, Marik J, Gandour-Edwards R, Kam KS,. Near-infrared optical imaging of ovarian cancer xenografts with novel alpha 3-integrin binding peptide "OA02 ". Mol Imaging 2005; 4: 437-439.
34. Tolmachev F, Wallberg H, Sandstrom M, Hansson M, Wennborg A, Orlova A,. Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels. Eur J Nuc Mol Imaging 2010; 38: 531-539.
35. Delord JP, Allal C, Canal M, Mery E, Rochiax P, Hennebelle I, Pradines A, Chatelut E, Bugat R, Guichard S, Canal P,. Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma. Ann Oncol 2005; 16: 1889-1897.
36. Yu J, Javier D, Yaseen MA, Nitin N, Richards-Kortum R, Anvari B, Wong MS,. Self-assembly synthesis, tumor cell targeting, and photothermal capabilities of antibody-coated indocyanine green nanocapsules. J Am Chem Soc 2010; 132: 1929-1938.
37. Bahmani B, Gupta S, Upadhyayula S, Vullev VI, Anvari B,. Effect of polyethylene glycol coatings on uptake of indocyanine green loaded nanocapsules by human spleen macrophages in vitro. J Biomed Opt 2011; 16: 051303.
38. Bahmani B, Vullev V, Anvari B,. Development of ant-HER2 conjugated ICG-loaded polymeric nanoparticles for targeted optical imaging of ovarian cancer. Reporters, markers, dyes, nanoparticles, and molecular probes for biomedical applications IV; 2012; San Francisco, CA. SPIE 8233: 1-6.
39. Upadhyayula S, Quinata T, Bishop S, Gupta S, Johnson NR, Bahmani B, Bozhiov K, Stubbs J, Jreij P, Nallagatle P, Vullev VI,. Coatings of polyethylene glycol for suppressing adhesion between solid microspheres and flat surfaces. Langmuir 2012; 28: 5059-5069.
40. Bahmani B, Bacon D, Anvari B,. Erythrocyte-derived photo-theranostic agents: Hybrid nano-vesicles containing indocyanine green for near infrared imaging and therapeutic applications. Sci Rep 2013; 3: 2180. doi: 2110.1038/srep02180.
41. Yaseen MA, Yu J, Wong MS, Anvari B,. In-vivo fluorescence imaging of mammalian organs using charge-assembled mesocapsule constructs containing indocyanine green. Opt Express 2008; 16: 20577-20587.
42. Yaseen MA, Yu J, Wong MS, Anvari B,. Laser-induced heating of dextran-coated mesocapsules containing indocyanine green. Biotechnol Prog 2007; 23: 1431-1440.
43. Yaseen MA, Yu J, Jung BS, Wong MS, Anvari B,. Biodistribution of encapsulated indocyanine green in healthy mice. Mol Pharm 2009; 6: 1321-1332.
44. Jung B, Vullev V, Anvari B,. Revisiting indocyanine green: Effects of serum and physiological temperature on absorption and fluorescence characteristics. IEEE J Sel Top Quant 2014; 20: 7000409.
45. van Dam GM, Themelis G, Crane LM, Harlaar NJ, Pleijhuis RG, Kelder W, Sarantopoulos A, de Jong JS, Arts HJ, van der Zee AG, Bart J, Low PS, Ntziachristos V,. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: First in-human results. Nat Med 2011; 17: 1315-1319.
46. van Scheltinga AGT, van Dam GM, Nagengast WB, Ntziachristos V, Hollema H, Herek JL, Schroder CP, Kosterink JGW, Lub-de Hoog MN, de Vries EGE,. Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. J Nucl Med 2011; 52: 1778-1785.
47. Alexander VM, Sano K, Yu Z, Nakajima T, Choyke PL, Ptaszek M, Kobayashi H,. Galactosyl human serum albumin-NMP1 conjugate: A near infrared [NIR]-activatable fluorescence imaging agent to detect peritoneal ovarian cancer metastases. Bioconjug Chem 2012; 23: 1671-1679.
48. Corbin IR, Ng KK, Ding L, Jurisicova A, Zheng G,. Near-infrared fluorescent imaging of metastatic ovarian cancer using folate receptor-targeted high-density lipoprotein nanocarriers. Nanomedicine [Lond] 2013; 8: 875-890.
49. Harlaar NJ, Kelder W, Sarantopoulos A, Bart J, Themelis G, van Dam GM, Ntziachristos V,. Real-time near infrared fluorescence [NIRF] intra-operative imaging in ovarian cancer using an αvβ3-integrin targeted agent. Gynecol Oncol 2013; 128: 590-595.
50. Kosaka N, Mitsunaga M, Longmire MR, Choyke PL, Kobayashi H,. Near infrared fluorescence-guided real-time endoscopic detection of peritoneal ovarian cancer nodules using intravenously injected indocyanine green. Int J Cancer 2011; 29: 1671-1677.
51. Matsumura Y, Maeda H,. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46: 6387-6392.
52. Torchilin V,. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 2011; 63: 131-135.
53. Lele SB, Piver MS, Mang TS, Dougherty TJ, Tomzak MJ,. Photodynamic therapy in gynecologic malignancies. Gynecol Oncol 1989; 34: 350-352.
54. Sindelar WF, DeLaney TF, Tochner Z, Thomas GF, Dachowski LJ, Smith PD, Friauf WS, Cole JW, Glatstein E,. Technique of photodynamic therapy for disseminated intraperitoneal malignant neoplasms phase I study. Arch Surg 1991; 126: 318-324.
55. DeLaney TF, Sindelar WF, Tochner Z, Smith PD, Friauf WS, Thomas G, Dachowski L, Cole JW, Steinberg SM, Glatstein E,. Phase I study of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors. Int J Radiat Oncol Biol Phys 1993; 15: 445-457.
56. Mir Y, Erlington SA, Hasan T,. A new nanoconstruct for epidermal growth factor receptor-targeted photo-immunotherapy of ovarian cancer. Nanomedicine: NBM 2013; 9: 1114-1122.
57. Tang Y, McGoron AJ,. Combined effects of laser-ICG photothermotherapy and doxorubicin chemotherapy on ovarian cancer cells. J Photochem Photobiol B 2009; 97: 138-144.
58. Chen W, Bardhan R, Bartles M, Perez-Torres C, Pautler RG, Halas NJ, Joshi A,. A molecularly targeted theranostic probe for ovarian cancer. Mol Cancer Ther 2010; 9: 1028-1038.
59. Hilderbrandt B, Wust P, Alhers O, Dieing A, Sreenivasa G, Kerner T, Felix R, Riess H,. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol 2002; 43: 33-56.